Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126


Designed reduction of Streptococcus pneumoniae pathogenicity via synthetic changes in virulence factor codon-pair bias.

Coleman JR, Papamichail D, Yano M, García-Suárez Mdel M, Pirofski LA.

J Infect Dis. 2011 May 1;203(9):1264-73. doi: 10.1093/infdis/jir010. Epub 2011 Feb 21.


Contributions of pneumolysin, pneumococcal surface protein A (PspA), and PspC to pathogenicity of Streptococcus pneumoniae D39 in a mouse model.

Ogunniyi AD, LeMessurier KS, Graham RM, Watt JM, Briles DE, Stroeher UH, Paton JC.

Infect Immun. 2007 Apr;75(4):1843-51. Epub 2007 Jan 29.


Dual function of pneumolysin in the early pathogenesis of murine pneumococcal pneumonia.

Rubins JB, Charboneau D, Paton JC, Mitchell TJ, Andrew PW, Janoff EN.

J Clin Invest. 1995 Jan;95(1):142-50.


Viability and virulence of pneumolysin, pneumococcal surface protein A, and pneumolysin/pneumococcal surface protein A mutants in the ear.

Schachern PA, Tsuprun V, Goetz S, Cureoglu S, Juhn SK, Briles DE, Paparella MM, Ferrieri P.

JAMA Otolaryngol Head Neck Surg. 2013 Sep;139(9):937-43. doi: 10.1001/jamaoto.2013.4104.


Novel role for the Streptococcus pneumoniae toxin pneumolysin in the assembly of biofilms.

Shak JR, Ludewick HP, Howery KE, Sakai F, Yi H, Harvey RM, Paton JC, Klugman KP, Vidal JE.

MBio. 2013 Sep 10;4(5):e00655-13. doi: 10.1128/mBio.00655-13.


Tissue-specific contributions of pneumococcal virulence factors to pathogenesis.

Orihuela CJ, Gao G, Francis KP, Yu J, Tuomanen EI.

J Infect Dis. 2004 Nov 1;190(9):1661-9. Epub 2004 Sep 21.


Pneumolysin with low hemolytic activity confers an early growth advantage to Streptococcus pneumoniae in the blood.

Harvey RM, Ogunniyi AD, Chen AY, Paton JC.

Infect Immun. 2011 Oct;79(10):4122-30. doi: 10.1128/IAI.05418-11. Epub 2011 Jul 25.


Insertion sequence 1515 in the ply gene of a type 1 clinical isolate of Streptococcus pneumoniae abolishes pneumolysin expression.

Garnier F, Janapatla RP, Charpentier E, Masson G, Grélaud C, Stach JF, Denis F, Ploy MC.

J Clin Microbiol. 2007 Jul;45(7):2296-7. Epub 2007 May 9.


Amino acid changes affecting the activity of pneumolysin alter the behaviour of pneumococci in pneumonia.

Alexander JE, Berry AM, Paton JC, Rubins JB, Andrew PW, Mitchell TJ.

Microb Pathog. 1998 Mar;24(3):167-74.


Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae.

Berry AM, Yother J, Briles DE, Hansman D, Paton JC.

Infect Immun. 1989 Jul;57(7):2037-42.


Streptococcus pneumoniae serine protease HtrA, but not SFP or PrtA, is a major virulence factor in pneumonia.

de Stoppelaar SF, Bootsma HJ, Zomer A, Roelofs JJ, Hermans PW, van 't Veer C, van der Poll T.

PLoS One. 2013 Nov 11;8(11):e80062. doi: 10.1371/journal.pone.0080062. eCollection 2013.


Upper and lower respiratory tract infection by Streptococcus pneumoniae is affected by pneumolysin deficiency and differences in capsule type.

Kadioglu A, Taylor S, Iannelli F, Pozzi G, Mitchell TJ, Andrew PW.

Infect Immun. 2002 Jun;70(6):2886-90.


Critical involvement of pneumolysin in production of interleukin-1alpha and caspase-1-dependent cytokines in infection with Streptococcus pneumoniae in vitro: a novel function of pneumolysin in caspase-1 activation.

Shoma S, Tsuchiya K, Kawamura I, Nomura T, Hara H, Uchiyama R, Daim S, Mitsuyama M.

Infect Immun. 2008 Apr;76(4):1547-57. doi: 10.1128/IAI.01269-07. Epub 2008 Jan 14.


Nuclear factor-kappaB activation in mouse lung lavage cells in response to Streptococcus pneumoniae pulmonary infection.

Amory-Rivier CF, Mohler J, Bédos JP, Azoulay-Dupuis E, Henin D, Muffat-Joly M, Carbon C, Moine P.

Crit Care Med. 2000 Sep;28(9):3249-56.


Ethanol-induced alcohol dehydrogenase E (AdhE) potentiates pneumolysin in Streptococcus pneumoniae.

Luong TT, Kim EH, Bak JP, Nguyen CT, Choi S, Briles DE, Pyo S, Rhee DK.

Infect Immun. 2015 Jan;83(1):108-19. doi: 10.1128/IAI.02434-14. Epub 2014 Oct 13.


Peptidoglycan Branched Stem Peptides Contribute to Streptococcus pneumoniae Virulence by Inhibiting Pneumolysin Release.

Greene NG, Narciso AR, Filipe SR, Camilli A.

PLoS Pathog. 2015 Jun 26;11(6):e1004996. doi: 10.1371/journal.ppat.1004996. eCollection 2015 Jun.


Toll-like receptor 2 contributes to antibacterial defence against pneumolysin-deficient pneumococci.

Dessing MC, Florquin S, Paton JC, van der Poll T.

Cell Microbiol. 2008 Jan;10(1):237-46. Epub 2007 Aug 17.

Supplemental Content

Support Center